drugset / Trial / NCT06055153
DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, exploratory clinical study.
Timeline
- Start
- 2023-09-30
- Primary completion
- 2025-02-28
- Completion
- 2025-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | Disitamab Vedotin | Other / unclassified | 2 mg/kg | Intravenous |
| Subject | Disitamab Vedotin | Other / unclassified | 2.5 mg/kg | Intravenous |
| Subject | Nedaplatin | Small molecule | 75 mg/m2 | — |